Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioavailability
Conditions
Bioavailability, B-cell Lymphoid Cancer
Trial Timeline
Jun 24, 2020 → Jan 20, 2021
NCT ID
NCT04488016About Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2 is a phase 1 stage product being developed by AstraZeneca for Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT04488016. Target conditions include Bioavailability, B-cell Lymphoid Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04488016 | Phase 1 | Completed |
Competing Products
20 competing products in Bioavailability